Navigation Links
Anti-HAV antibodies in beta-thalassemia
Date:4/30/2008

Thalassemic patients were found to present a higher prevalence of anti-HAV IgG antibodies than matched healthy subjects from the same geographic area. This finding is difficult to explain, but it may be attributed to the higher vulnerability of thalassemics to HAV infection and to passive transfer of anti-HAV antibodies by blood transfusion.

This study, performed by a team led by Associate Professor C Labropoulou-Karatza and Dr D Siagris, is described in a research article to be published on March 14, 2008, in the World Journal of Gastroenterology.

In Greece, the lack of Hepatitis A epidemics since the early 1980s and the improvement of socioeconomic and hygienic conditions over the last decade seem to have contributed to a decline in prevalence of anti-HAV antibodies. However, the authors observed that the majority of their beta-thalassemia patients were anti-HAV-IgG-positive.

In the view of the authors, the findings of this study are in contradiction with those of previous studies which showed a lower prevalence of anti-HAV antibodies in thalassemic patients.

In order to further reduce the incidence of liver infections in multitransfused thalassemic patients, the authors recommend active immunization for HAV in that population.

In the view of the reviewers, the strength of this study is surely due to the dimension of the population and the long history of the patients (10 years).

Further research, including testing the prevalence of anti-HAV antibodies in family members of thalassemia patients and in the frozen aliquots of donors plasma, would confirm these findings.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring
4. Autoantibodies and neuropsychiatric events in lupus
5. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
6. Gene variant linked to moderated symptoms of beta-thalassemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, ... ... a non-profit medical society dedicated to advancing the science and clinical practice ... from its RSSearch Patient Registry, a multi-institutional, observational registry established to standardize ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical ... begin serving as new board chair for Orange County health care system CalOptima ... remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
(Date:3/28/2017)... 2017 The global market for ... the top three companies, namely Shimadzu Corporation, Thermo Fisher ... 49% of the overall market in 2015, observes Transparency ... is intensely competitive and has few players, most of ... factors have restricted the entry of new players in ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 /PRNewswire/ ... Israel . This new business entity, Emosis Ltd, headquartered ... to research and development of novel assays complementing the mother company ... relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move starts ...
Breaking Medicine Technology: